Replication is a highly regulated process that guarantees the faithful duplication of the genome once per cell cycle, and any condition that compromises it is referred to as replication stress.
Replication stress is a major cause of genome instability and is linked to pre-tumour and tumour cells. Several oncogenes cause alterations of replication timing and progression, leading to replication stress.
The DNA-damage checkpoint responds to replication stress to guarantee genome stability by protecting stalled forks and promoting replication completion through the activation of dormant replication origins.
DNA repair pathways such as homologous recombination restore replication upon DNA breaks that occur at stalled forks.
Failures in the cellular response to replication stress, such as those caused by dysfunctions of the DNA-damage checkpoint, replication fork restart or DNA repair, are tumorigenic, as seen in mouse models and human syndromes.
Replication stress is not a common feature of normal cells; therefore, it opens up new possibilities for cancer diagnostics and treatment.
Genome instability is a hallmark of cancer, and DNA replication is the most vulnerable cellular process that can lead to it. Any condition leading to high levels of DNA damage will result in replication stress, which is a source of genome instability and a feature of pre-cancerous and cancerous cells. Therefore, understanding the molecular basis of replication stress is crucial to the understanding of tumorigenesis. Although a negative aspect of replication stress is its prominent role in tumorigenesis, a positive aspect is that it provides a potential target for cancer therapy. In this Review, we discuss the link between persistent replication stress and tumorigenesis, with the goal of shedding light on the mechanisms underlying the initiation of an oncogenic process, which should open up new possibilities for cancer diagnostics and treatment.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Collins, A. R. Oxidative DNA damage, antioxidants, and cancer. Bioessays 21, 238–246 (1999).
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
Hills, S. A. & Diffley, J. F. DNA replication and oncogene-induced replicative stress. Curr. Biol. 24, R435–R444 (2014).
Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005).
Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005). References 4 and 5 provide compelling evidence for the connection between DNA replication stress and carcinogenesis from its early stages, to DNA damage and intra-S checkpoint activation. These results support the idea that DNA checkpoints act as a barrier to tumorigenesis and that their constitutive activation exerts a selective pressure on p53 mutations.
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642 (2006).
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Durkin, S. G. et al. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc. Natl Acad. Sci. USA 105, 246–251 (2008).
Bilousova, G., Marusyk, A., Porter, C. C., Cardiff, R. D. & DeGregori, J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol. 3, e401 (2005).
Aguilera, A. & Garcia-Muse, T. Causes of genome instability. Annu. Rev. Genet. 47, 1–32 (2013).
Boos, D., Frigola, J. & Diffley, J. F. Activation of the replicative DNA helicase: breaking up is hard to do. Curr. Opin. Cell Biol. 24, 423–430 (2012).
Blow, J. J., Ge, X. Q. & Jackson, D. A. How dormant origins promote complete genome replication. Trends Biochem. Sci. 36, 405–414 (2011).
Shechter, D., Costanzo, V. & Gautier, J. ATR and ATM regulate the timing of DNA replication origin firing. Nature Cell Biol. 6, 648–655 (2004).
Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542–1548 (2003).
Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biol. 8, 37–45 (2006).
Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155, 1088–1103 (2013). This study demonstrates that ATR-mediated origin inactivation in response to replicative checkpoint activation prevents nucleus-wide DNA breakage and thus the exhaustion of the nuclear pool of RPA. Importantly, RPA availability seems to considerably influence the magnitude of fork breakage.
O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nature Genet. 33, 497–501 (2003).
Murga, M. et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature Struct. Mol. Biol. 18, 1331–1335 (2011).
Gilad, O. et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 70, 9693–9702 (2010).
Koniaras, K., Cuddihy, A. R., Christopoulos, H., Hogg, A. & O'Connell, M. J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20, 7453–7463 (2001).
Abdel-Fatah, T. M. et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol. Oncol. 9, 569–585 (2015).
Lopez-Contreras, A. J., Gutierrez-Martinez, P., Specks, J., Rodrigo-Perez, S. & Fernandez-Capetillo, O. An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation. J. Exp. Med. 209, 455–461 (2012).
Brown, E. J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397–402 (2000).
Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14, 1448–1459 (2000).
Tho, L. M., Libertini, S., Rampling, R., Sansom, O. & Gillespie, D. A. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene 31, 1366–1375 (2012).
Vassileva, V., Millar, A., Briollais, L., Chapman, W. & Bapat, B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 62, 4095–4099 (2002).
Menoyo, A. et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 61, 7727–7730 (2001).
Ibarra, A., Schwob, E. & Mendez, J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl Acad. Sci. USA 105, 8956–8961 (2008).
Ge, X. Q., Jackson, D. A. & Blow, J. J. Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev. 21, 3331–3341 (2007).
Kawabata, T. et al. Stalled fork rescue via dormant replication origins in unchallenged S phase promotes proper chromosome segregation and tumor suppression. Mol. Cell 41, 543–553 (2011).
Shima, N. et al. A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nature Genet. 39, 93–98 (2007).
Letessier, A. et al. Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 470, 120–123 (2011).
Ozeri-Galai, E. et al. Failure of origin activation in response to fork stalling leads to chromosomal instability at fragile sites. Mol. Cell 43, 122–131 (2011).
Ekholm-Reed, S. et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol. 165, 789–800 (2004).
Li, A. & Blow, J. J. Cdt1 downregulation by proteolysis and geminin inhibition prevents DNA re-replication in Xenopus. EMBO J. 24, 395–404 (2005).
Davidson, I. F., Li, A. & Blow, J. J. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol. Cell 24, 433–443 (2006).
Vaziri, C. et al. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 11, 997–1008 (2003).
Melixetian, M. et al. Loss of Geminin induces rereplication in the presence of functional p53. J. Cell Biol. 165, 473–482 (2004).
Liontos, M. et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res. 67, 10899–10909 (2007).
Aggarwal, P. et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 21, 2908–2922 (2007).
Tardat, M. et al. The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells. Nature Cell Biol. 12, 1086–1093 (2010).
Black, J. C. et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154, 541–555 (2013).
Dominguez-Sola, D. & Gautier, J. MYC and the control of DNA replication. Cold Spring Harb. Perspect. Med. 4, a014423 (2014).
Dominguez-Sola, D. et al. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445–451 (2007). This work demonstrates that MYC physically interacts with replication factors and participates in the control of DNA replication timing. Importantly, these new functions are totally independent of transcription.
Srinivasan, S. V., Dominguez-Sola, D., Wang, L. C., Hyrien, O. & Gautier, J. Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep. 3, 1629–1639 (2013).
Frum, R. A. et al. The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing. Nucleic Acids Res. 42, 926–940 (2014).
Neelsen, K. J. et al. Deregulated origin licensing leads to chromosomal breaks by rereplication of a gapped DNA template. Genes Dev. 27, 2537–2542 (2013).
Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435–446 (2011). This work shows that supplying nucleosides is sufficient to rescue the replication stress and DNA damage induced by oncogene activation and considerably decreases tumorigenesis.
Xie, M. et al. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase. Cancer Res. 74, 212–223 (2014).
Bartek, J., Lukas, C. & Lukas, J. Checking on DNA damage in S phase. Nature Rev. Mol. Cell Biol. 5, 792–804 (2004).
Moldovan, G. L. & D'Andrea, A. D. How the fanconi anemia pathway guards the genome. Annu. Rev. Genet. 43, 223–249 (2009).
Gaillard, H., Herrera-Moyano, E. & Aguilera, A. Transcription-associated genome instability. Chem. Rev. 113, 8638–8661 (2013).
Gottipati, P., Cassel, T. N., Savolainen, L. & Helleday, T. Transcription-associated recombination is dependent on replication in mammalian cells. Mol. Cell. Biol. 28, 154–164 (2008).
Jones, R. M. et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 32, 3744–3753 (2013).
Neelsen, K. J., Zanini, I. M., Herrador, R. & Lopes, M. Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates. J. Cell Biol. 200, 699–708 (2013).
Tuduri, S. et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nature Cell Biol. 11, 1315–1324 (2009).
Dominguez-Sanchez, M. S., Barroso, S., Gomez-Gonzalez, B., Luna, R. & Aguilera, A. Genome instability and transcription elongation impairment in human cells depleted of THO/TREX. PLoS Genet. 7, e1002386 (2011).
Paulsen, R. D. et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol. Cell 35, 228–239 (2009).
Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 44, 966–977 (2011).
Herrera-Moyano, E., Mergui, X., Garcia-Rubio, M. L., Barroso, S. & Aguilera, A. The yeast and human FACT chromatin-reorganizing complexes solve R-loop-mediated transcription-replication conflicts. Genes Dev. 28, 735–748 (2014).
Bhatia, V. et al. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511, 362–365 (2014). This work shows that BRCA2-depleted or BRCA2-deficient cancer cells accumulate R-loops and DNA damage, and that genome instability generated in such cells is partially dependent on R-loops. This work provides a novel role for BRCA2 in preventing or helping to remove R-loops and proposes that these R-loops are a major source of replication stress in cancer cells.
Nie, Z. et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79 (2012).
Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012).
Sabo, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488–492 (2014).
Brosh, R. M. Jr. DNA helicases involved in DNA repair and their roles in cancer. Nature Rev. Cancer 13, 542–558 (2013).
Thangavel, S. et al. Human RECQ1 and RECQ4 helicases play distinct roles in DNA replication initiation. Mol. Cell. Biol. 30, 1382–1396 (2010).
Popuri, V., Croteau, D. L., Brosh, R. M. Jr & Bohr, V. A. RECQ1 is required for cellular resistance to replication stress and catalyzes strand exchange on stalled replication fork structures. Cell Cycle 11, 4252–4265 (2012).
Saponaro, M. et al. RECQL5 controls transcript elongation and suppresses genome instability associated with transcription stress. Cell 157, 1037–1049 (2014).
Pichierri, P., Franchitto, A., Mosesso, P. & Palitti, F. Werner's syndrome protein is required for correct recovery after replication arrest and DNA damage induced in S-phase of cell cycle. Mol. Biol. Cell 12, 2412–2421 (2001).
Davies, S. L., North, P. S. & Hickson, I. D. Role for BLM in replication-fork restart and suppression of origin firing after replicative stress. Nature Struct. Mol. Biol. 14, 677–679 (2007).
Machwe, A., Karale, R., Xu, X., Liu, Y. & Orren, D. K. The Werner and Bloom syndrome proteins help resolve replication blockage by converting (regressed) holliday junctions to functional replication forks. Biochemistry 50, 6774–6788 (2011).
Schwartz, E. K. & Heyer, W. D. Processing of joint molecule intermediates by structure-selective endonucleases during homologous recombination in eukaryotes. Chromosoma 120, 109–127 (2011).
Hanada, K. et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nature Struct. Mol. Biol. 14, 1096–1104 (2007).
Fugger, K. et al. FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress. Nature Commun. 4, 1–8 (2013).
Jeong, Y. T. et al. FBH1 promotes DNA double-strand breakage and apoptosis in response to DNA replication stress. J. Cell Biol. 200, 141–149 (2013).
Murfuni, I. et al. The WRN and MUS81 proteins limit cell death and genome instability following oncogene activation. Oncogene 32, 610–620 (2013).
Luebben, S. W., Kawabata, T., Johnson, C. S., O'Sullivan, M. G. & Shima, N. A concomitant loss of dormant origins and FANCC exacerbates genome instability by impairing DNA replication fork progression. Nucleic Acids Res. 42, 5605–5615 (2014).
Ciccia, A., McDonald, N. & West, S. C. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu. Rev. Biochem. 77, 259–287 (2008).
Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001).
Wang, X., Andreassen, P. R. & D'Andrea, A. D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell. Biol. 24, 5850–5862 (2004).
Murina, O. et al. FANCD2 and CtIP cooperate to repair DNA interstrand crosslinks. Cell Rep. 7, 1030–1038 (2014).
Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol. Cell 39, 25–35 (2010).
Pathania, S. et al. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol. Cell 44, 235–251 (2011).
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 17, 3017–3022 (2003).
Petermann, E., Orta, M. L., Issaeva, N., Schultz, N. & Helleday, T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol. Cell 37, 492–502 (2010).
Willis, N. A. et al. BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks. Nature 510, 556–559 (2014).
Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529–542 (2011).
Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22, 106–116 (2012).
Lossaint, G. et al. FANCD2 binds MCM proteins and controls replisome function upon activation of S phase checkpoint signaling. Mol. Cell 51, 678–690 (2013).
Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009–1023 (1996).
Patel, K. J. et al. Involvement of Brca2 in DNA repair. Mol. Cell 1, 347–357 (1998).
Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genet. 28, 266–271 (2001).
Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418–425 (2001).
Houghtaling, S. et al. Heterozygosity for p53 (Trp53+/−) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res. 65, 85–91 (2005).
Hill, S. J. et al. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev. 28, 1957–1975 (2014).
Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015).
Klein, H. L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst.) 7, 686–693 (2008).
Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nature Rev. Cancer 11, 96–110 (2011).
Pan, Q., Fang, Y., Xu, Y., Zhang, K. & Hu, X. Down-regulation of DNA polymerases κ, η, ι, and ζ in human lung, stomach, and colorectal cancers. Cancer Lett. 217, 139–147 (2005).
Buisson, R. et al. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks. Cell Rep. 6, 553–564 (2014).
McCulloch, S. D. et al. Preferential cis-syn thymine dimer bypass by DNA polymerase η occurs with biased fidelity. Nature 428, 97–100 (2004).
Rey, L. et al. Human DNA polymerase η is required for common fragile site stability during unperturbed DNA replication. Mol. Cell. Biol. 29, 3344–3354 (2009).
Lange, S. S., Wittschieben, J. P. & Wood, R. D. DNA polymerase ζ is required for proliferation of normal mammalian cells. Nucleic Acids Res. 40, 4473–4482 (2012).
Mailand, N., Gibbs-Seymour, I. & Bekker-Jensen, S. Regulation of PCNA-protein interactions for genome stability. Nature Rev. Mol. Cell Biol. 14, 269–282 (2013).
Lin, J. R., Zeman, M. K., Chen, J. Y., Yee, M. C. & Cimprich, K. A. SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. Mol. Cell 42, 237–249 (2011).
Motegi, A. et al. Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. Proc. Natl Acad. Sci. USA 105, 12411–12416 (2008).
Moinova, H. R. et al. HLTF gene silencing in human colon cancer. Proc. Natl Acad. Sci. USA 99, 4562–4567 (2002).
Millikin, D., Meese, E., Vogelstein, B., Witkowski, C. & Trent, J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 51, 5449–5453 (1991).
Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Struct. Mol. Biol. 17, 688–695 (2010).
Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010). Together, references 110 and 111 demonstrate that loss of the NHEJ factor 53BP1 restores error-free repair by HR in BRCA1-deficient cells. These results indicate that 53BP1 and BRCA1 have crucial roles in the regulation of the choice between the NHEJ and HR repair pathways.
Thorslund, T. et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nature Struct. Mol. Biol. 17, 1263–1265 (2010).
Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl Acad. Sci. USA 103, 8768–8773 (2006).
Bunting, S. F. & Nussenzweig, A. End-joining, translocations and cancer. Nature Rev. Cancer 13, 443–454 (2013).
Tischkowitz, M. et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc. Natl Acad. Sci. USA 104, 6788–6793 (2007).
Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371, 497–506 (2014).
Bolderson, E. et al. Human single-stranded DNA binding protein 1 (hSSB1/NABP2) is required for the stability and repair of stalled replication forks. Nucleic Acids Res. 42, 6326–6336 (2014).
Shi, W. et al. Essential developmental, genomic stability, and tumour suppressor functions of the mouse orthologue of hSSB1/NABP2. PLoS Genet. 9, e1003298 (2013).
Wang, Y. et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nature Genet. 37, 750–755 (2005).
Wechsler, T., Newman, S. & West, S. C. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 471, 642–646 (2011).
Gisselsson, D. et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc. Natl Acad. Sci. USA 97, 5357–5362 (2000).
Janssen, A., van der Burg, M., Szuhai, K., Kops, G. J. & Medema, R. H. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 333, 1895–1898 (2011).
Wilhelm, T. et al. Spontaneous slow replication fork progression elicits mitosis alterations in homologous recombination-deficient mammalian cells. Proc. Natl Acad. Sci. USA 111, 763–768 (2014).
Thompson, S. L. & Compton, D. A. Chromosome missegregation in human cells arises through specific types of kinetochore-microtubule attachment errors. Proc. Natl Acad. Sci. USA 108, 17974–17978 (2011).
Crasta, K. et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 482, 53–58 (2012).
Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
Dick, F. A. & Rubin, S. M. Molecular mechanisms underlying RB protein function. Nature Rev. Mol. Cell Biol. 14, 297–306 (2013).
Manning, A. L. et al. Suppression of genome instability in pRB-deficient cells by enhancement of chromosome cohesion. Mol. Cell 53, 993–1004 (2014).
Chan, K. L., North, P. S. & Hickson, I. D. BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. EMBO J. 26, 3397–3409 (2007).
Chan, K. L., Palmai-Pallag, T., Ying, S. & Hickson, I. D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nature Cell Biol. 11, 753–760 (2009).
Naim, V. & Rosselli, F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nature Cell Biol. 11, 761–768 (2009). References 130 and 131 provide evidence supporting the idea that unresolved replication or recombination intermediates resulting from replication stress remain interlinked through ultra-fine DNA bridges as cells go through mitosis. These studies show that the FA and Bloom pathways collaborate to avoid or resolve such situations and to promote accurate chromosome segregation.
Ying, S. et al. MUS81 promotes common fragile site expression. Nature Cell Biol. 15, 1001–1007 (2013).
Naim, V., Wilhelm, T., Debatisse, M. & Rosselli, F. ERCC1 and MUS81-EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis. Nature Cell Biol. 15, 1008–1015 (2013).
Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013). In this study, analysis of colorectal cancer cells with cancer chromosomal instability revealed that they undergo replication stress and that this replication stress contributes to both structural abnormalities and chromosome missegregation.
Gad, H. et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508, 215–221 (2014).
Huber, K. V. et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508, 222–227 (2014).
Steckel, M. et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227–1245 (2012).
Zimmerman, K. M., Jones, R. M., Petermann, E. & Jeggo, P. A. Diminished origin-licensing capacity specifically sensitizes tumor cells to replication stress. Mol. Cancer Res. 11, 370–380 (2013).
Zhu, W. & Depamphilis, M. L. Selective killing of cancer cells by suppression of geminin activity. Cancer Res. 69, 4870–4877 (2009).
Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U. & Dutta, A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70, 10310–10320 (2010).
Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071–1078 (2009).
Wang, Q. et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl Cancer Inst. 88, 956–965 (1996).
Fishler, T. et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29, 4007–4017 (2010).
Kawasumi, M. et al. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proc. Natl Acad. Sci. USA 108, 13716–13721 (2011).
Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chem. Biol. 7, 428–430 (2011).
Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nature Struct. Mol. Biol. 18, 721–727 (2011).
Charrier, J. D. et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 54, 2320–2330 (2011).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Michels, J., Vitale, I., Saparbaev, M., Castedo, M. & Kroemer, G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 33, 3894–3907 (2014).
Nicolay, N. H., Helleday, T. & Sharma, R. A. Biological relevance of DNA polymerase β and translesion synthesis polymerases to cancer and its treatment. Curr. Mol. Pharmacol. 5, 54–67 (2012).
Zucca, E. et al. Silencing of human DNA polymerase λ causes replication stress and is synthetically lethal with an impaired S phase checkpoint. Nucleic Acids Res. 41, 229–241 (2013).
Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 343, 88–91 (2014).
Masai, H., Matsumoto, S., You, Z., Yoshizawa-Sugata, N. & Oda, M. Eukaryotic chromosome DNA replication: where, when, and how? Annu. Rev. Biochem. 79, 89–130 (2010).
Durkin, S. G. & Glover, T. W. Chromosome fragile sites. Annu. Rev. Genet. 41, 169–192 (2007).
Debatisse, M., Le Tallec, B., Letessier, A., Dutrillaux, B. & Brison, O. Common fragile sites: mechanisms of instability revisited. Trends Genet. 28, 22–32 (2012).
Lahiri, M., Gustafson, T. L., Majors, E. R. & Freudenreich, C. H. Expanded CAG repeats activate the DNA damage checkpoint pathway. Mol. Cell 15, 287–293 (2004).
Casper, A. M., Nghiem, P., Arlt, M. F. & Glover, T. W. ATR regulates fragile site stability. Cell 111, 779–789 (2002).
Yunis, J. J. & Soreng, A. L. Constitutive fragile sites and cancer. Science 226, 1199–1204 (1984).
Burrow, A. A., Williams, L. E., Pierce, L. C. & Wang, Y. H. Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics http://dx.doi.org/10.1186/1471-2164-10-59 (2009).
Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893–898 (2010).
Tsantoulis, P. K. et al. Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene 27, 3256–3264 (2008).
Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E. & Wang, Y. H. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29, 2272–2280 (2010).
Hellman, A. et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 1, 89–97 (2002).
Blumrich, A. et al. The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers. Hum. Mol. Genet. 20, 1488–1501 (2011).
Ohta, M. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587–597 (1996).
Corbin, S. et al. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res. 62, 3477–3484 (2002).
Aqeilan, R. I. et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc. Natl Acad. Sci. USA 104, 3949–3954 (2007).
Gong, Y. et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genet. 46, 588–594 (2014).
Le Tallec, B. et al. Molecular profiling of common fragile sites in human fibroblasts. Nature Struct. Mol. Biol. 18, 1421–1423 (2011).
Le Tallec, B. et al. Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes. Cell Rep. 4, 420–428 (2013).
Barlow, J. H. et al. Identification of early replicating fragile sites that contribute to genome instability. Cell 152, 620–632 (2013). This work identifies a novel type of fragile site in B lymphocytes. These sites replicate early, in contrast to common fragile sites, and colocalize with highly expressed gene clusters. Importantly, many recurrent amplifications and deletions found in human lymphomas map to these fragile genomic sites.
Ogrunc, M. et al. Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ. 21, 998–1012 (2014).
Aguilera, A. & Gaillard, H. Transcription and recombination: when RNA meets DNA. Cold Spring Harb Perspect Biol 6, a016543 (2014).
Arentson, E. et al. Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 21, 1150–1158 (2002).
Seo, J. et al. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene 24, 8176–8186 (2005).
Pruitt, S. C., Bailey, K. J. & Freeland, A. Reduced Mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells 25, 3121–3132 (2007).
Kucherlapati, M. et al. Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression. Proc. Natl Acad. Sci. USA 99, 9924–9929 (2002).
Zheng, L. et al. Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nature Med. 13, 812–819 (2007).
Larsen, E. et al. Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants. Cancer Res. 68, 4571–4579 (2008).
Xu, X. et al. Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res. 68, 2652–2660 (2008).
Rahman, L. et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5, 341–351 (2004).
Chen, M. et al. Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 26, 4817–4824 (2007).
Fang, Y. et al. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J. 23, 3164–3174 (2004).
Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159–171 (1996).
Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411–2422 (1996).
Elson, A. et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl Acad. Sci. USA 93, 13084–13089 (1996).
Niida, H. et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. EMBO J. 29, 3558–3570 (2010).
Stracker, T. H., Couto, S. S., Cordon-Cardo, C., Matos, T. & Petrini, J. H. Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol. Cell 31, 21–32 (2008).
Lin, Q. et al. Increased susceptibility to UV-induced skin carcinogenesis in polymerase η-deficient mice. Cancer Res. 66, 87–94 (2006).
Wittschieben, J. P. et al. Loss of DNA polymerase ζ enhances spontaneous tumorigenesis. Cancer Res. 70, 2770–2778 (2010).
Hu, Y. et al. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. Genes Dev. 21, 3073–3084 (2007).
Mann, M. B. et al. Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum. Mol. Genet. 14, 813–825 (2005).
Luo, G. et al. Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nature Genet. 26, 424–429 (2000).
Pamidi, A. et al. Functional interplay of p53 and Mus81 in DNA damage responses and cancer. Cancer Res. 67, 8527–8535 (2007).
Hodskinson, M. R. et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol. Cell 54, 472–484 (2014).
Xu, X. et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genet. 22, 37–43 (1999).
Ludwig, T., Fisher, P., Ganesan, S. & Efstratiadis, A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev. 15, 1188–1193 (2001).
Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nature Genet. 17, 423–430 (1997).
Houghtaling, S. et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 17, 2021–2035 (2003).
The authors would like to thank O. Fernandez-Capetillo and P. Huertas for their comments on the manuscript and D. Haun for style supervision. Research in A.A.'s laboratory is funded by grants from the Spanish Ministry of Economy and Competitiveness, the Junta de Andalucía, the European Union (FEDER), Worldwide Cancer Research and PharmaMar. The authors apologize to those whose work could not be cited owing to space limitations.
The authors declare no competing financial interests.
A sustained growth arrest in which cells are refractory to mitogen stimulation and apoptosis.
- Replication fork
DNA region at which unwinding of the double helix and synthesis of the complementary strands occur.
- S phase checkpoints
The quality-control mechanisms that guarantee genome integrity during DNA replication.
A protein complex involved in DNA replication that moves along the DNA as the nascent complementary strands are synthesized.
- Seckel syndrome
A rare autosomal recessive disorder, due to mutations in the ATR gene, which is characterized by intrauterine growth retardation, dwarfism, microcephaly with severe mental retardation and a bird-headed facial appearance.
- Hypomorphic mice
Transgenic mice carrying a mutation that causes a partial decrease in the activity of the affected gene.
- Replication intermediates
DNA structures formed transiently during the process of replication.
- DNA primase
Enzyme that catalyses the synthesis of a short RNA segment called a primer that is needed by DNA polymerases to start DNA synthesis.
- Replication fork collisions
Physical encounters between an advancing replication fork and another on-going process, such as transcription, taking place on the same DNA molecule.
- Non-B DNA structures
Secondary DNA structures that are different from right-handed double helical B DNA structures.
- Reversed forks
DNA structures that are formed when the nascent leading strand hybridizes to the corresponding lagging strand at a replication fork.
Small dilated blood vessels in the outer layer of the skin.
- Homologous recombination
(HR). Error-free double-strand break repair pathway that involves identical or homologous DNA sequences as templates.
- Non-homologous end joining
(NHEJ). Error-prone double-strand break repair pathway that directly ligates DNA ends.
- Loss of heterozygosity
(LOH). Loss of the wild-type allele of a diploid cell by deletion, gene conversion or chromosome loss.
Lack of chromosome segregation that gives rise to daughter cells with an abnormal number of chromosomes.
- Anaphase bridges
String-like DNA fibres connecting two nuclei during chromosome segregation due to unresolved recombination or replication intermediates.
Cycles of chromosome truncation and rescue by fusion of replicated sister chromatids resulting in chromosome rearrangements.
- Cleavage furrow
Infolding of the cell membrane at the equatorial plane of the cell occurring during cytokinesis.
About this article
Cite this article
Gaillard, H., García-Muse, T. & Aguilera, A. Replication stress and cancer. Nat Rev Cancer 15, 276–289 (2015). https://doi.org/10.1038/nrc3916
Science Advances (2021)
Cancer Letters (2021)
Trends in Cell Biology (2021)
Journal of Cell Biology (2021)
Critical Reviews in Clinical Laboratory Sciences (2021)